Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 314

1.

Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.

McKay RR, Gray KP, Hayes JH, Bubley GJ, Rosenberg JE, Hussain A, Kantoff PW, Taplin ME.

Cancer. 2015 Apr 22. doi: 10.1002/cncr.29398. [Epub ahead of print]

PMID:
25903013
2.

Androgen deprivation therapy reversibly increases endothelium-dependent vasodilation in men with prostate cancer.

Nguyen PL, Jarolim P, Basaria S, Zuflacht JP, Milian J, Kadivar S, Graham PL, Hyatt A, Kantoff PW, Beckman JA.

J Am Heart Assoc. 2015 Apr 20;4(4). pii: e001914. doi: 10.1161/JAHA.115.001914.

3.

DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors.

Bambury RM, Bhatt AS, Riester M, Pedamallu CS, Duke F, Bellmunt J, Stack EC, Werner L, Park R, Iyer G, Loda M, Kantoff PW, Michor F, Meyerson M, Rosenberg JE.

BMC Cancer. 2015 Apr 9;15:242. doi: 10.1186/s12885-015-1192-2.

4.

PLZF, a Tumor Suppressor Genetically Lost in Metastatic Castration-Resistant Prostate Cancer, Is a Mediator of Resistance to Androgen Deprivation Therapy.

Hsieh CL, Botta G, Gao S, Li T, Van Allen EM, Treacy DJ, Cai C, He HH, Sweeney CJ, Brown M, Balk SP, Nelson PS, Garraway LA, Kantoff PW.

Cancer Res. 2015 Mar 25. [Epub ahead of print]

PMID:
25808865
5.

Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases.

Helfand BT, Roehl KA, Cooper PR, McGuire BB, Fitzgerald LM, Cancel-Tassin G, Cornu JN, Bauer S, Van Blarigan EL, Chen X, Duggan D, Ostrander EA, Gwo-Shu M, Zhang ZF, Chang SC, Jeong S, Fontham ET, Smith G, Mohler JL, Berndt SI, McDonnell SK, Kittles R, Rybicki BA, Freedman M, Kantoff PW, Pomerantz M, Breyer JP, Smith JR, Rebbeck TR, Mercola D, Isaacs WB, Wiklund F, Cussenot O, Thibodeau SN, Schaid DJ, Cannon-Albright L, Cooney KA, Chanock SJ, Stanford JL, Chan JM, Witte J, Xu J, Bensen JT, Taylor JA, Catalona WJ.

Hum Genet. 2015 Apr;134(4):439-50. doi: 10.1007/s00439-015-1534-9. Epub 2015 Feb 26.

PMID:
25715684
6.

GermLine Variation in Superoxide Dismutase-2 (SOD2) and Survival Outcomes After Radiation Therapy for Prostate Cancer: Results of a Test and Validation Set Analysis.

Margalit DN, Jordahl KM, Werner L, Wang X, Gwo-Shu Lee M, Penney KL, Batista JL, Martin NE, Chan JM, Kantoff PW, Stampfer MJ, Nguyen PL, Mucci LA.

Clin Genitourin Cancer. 2015 Jan 3. pii: S1558-7673(14)00292-4. doi: 10.1016/j.clgc.2014.12.018. [Epub ahead of print]

PMID:
25662905
7.

Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results.

Morris MJ, Molina A, Small EJ, de Bono JS, Logothetis CJ, Fizazi K, de Souza P, Kantoff PW, Higano CS, Li J, Kheoh T, Larson SM, Matheny SL, Naini V, Burzykowski T, Griffin TW, Scher HI, Ryan CJ.

J Clin Oncol. 2015 Apr 20;33(12):1356-63. doi: 10.1200/JCO.2014.55.3875. Epub 2015 Jan 26.

PMID:
25624432
8.

Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease.

Tsao CK, Gray KP, Nakabayashi M, Evan C, Kantoff PW, Huang J, Galsky MD, Pomerantz M, Oh WK.

J Urol. 2015 Jan 24. pii: S0022-5347(15)00168-8. doi: 10.1016/j.juro.2015.01.078. [Epub ahead of print]

PMID:
25623747
9.

Emerging players in prostate cancer: long non-coding RNAs.

Sun T, Ye H, Wu CL, Lee GS, Kantoff PW.

Am J Clin Exp Urol. 2014 Dec 25;2(4):294-9. eCollection 2014. Review.

10.

Role of diet in prostate cancer: the epigenetic link.

Labbé DP, Zadra G, Ebot EM, Mucci LA, Kantoff PW, Loda M, Brown M.

Oncogene. 2014 Dec 22. doi: 10.1038/onc.2014.422. [Epub ahead of print] Review.

PMID:
25531313
11.

The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer.

Tamae D, Mostaghel E, Montgomery B, Nelson PS, Balk SP, Kantoff PW, Taplin ME, Penning TM.

Chem Biol Interact. 2015 Jun 5;234:332-8. doi: 10.1016/j.cbi.2014.12.012. Epub 2014 Dec 13.

PMID:
25514466
12.

Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.

Chen EJ, Sowalsky AG, Gao S, Cai C, Voznesensky O, Schaefer R, Loda M, True LD, Ye H, Troncoso P, Lis RL, Kantoff PW, Montgomery RB, Nelson PS, Bubley GJ, Balk SP, Taplin ME.

Clin Cancer Res. 2015 Mar 15;21(6):1273-80. doi: 10.1158/1078-0432.CCR-14-1220. Epub 2014 Oct 15.

PMID:
25320358
13.

Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.

Taplin ME, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, Sanda MG, Davis JW, Loda M, True LD, Troncoso P, Ye H, Lis RT, Marck BT, Matsumoto AM, Balk SP, Mostaghel EA, Penning TM, Nelson PS, Xie W, Jiang Z, Haqq CM, Tamae D, Tran N, Peng W, Kheoh T, Molina A, Kantoff PW.

J Clin Oncol. 2014 Nov 20;32(33):3705-15. doi: 10.1200/JCO.2013.53.4578. Epub 2014 Oct 13.

PMID:
25311217
14.

A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T.

McNeel DG, Gardner TA, Higano CS, Kantoff PW, Small EJ, Wener MH, Sims RB, DeVries T, Sheikh NA, Dreicer R.

Cancer Immunol Res. 2014 Oct;2(10):988-99. doi: 10.1158/2326-6066.CIR-14-0073. Epub 2014 Sep 4.

PMID:
25189164
15.

Contemporary nationwide patterns of self-reported prostate-specific antigen screening.

Sammon JD, Pucheril D, Diaz M, Kibel AS, Kantoff PW, Menon M, Trinh QD.

JAMA Intern Med. 2014 Nov;174(11):1839-41. doi: 10.1001/jamainternmed.2014.4117. No abstract available.

PMID:
25179266
16.

Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

MacConaill LE, Garcia E, Shivdasani P, Ducar M, Adusumilli R, Breneiser M, Byrne M, Chung L, Conneely J, Crosby L, Garraway LA, Gong X, Hahn WC, Hatton C, Kantoff PW, Kluk M, Kuo F, Jia Y, Joshi R, Longtine J, Manning A, Palescandolo E, Sharaf N, Sholl L, van Hummelen P, Wade J, Wollinson BM, Zepf D, Rollins BJ, Lindeman NI.

J Mol Diagn. 2014 Nov;16(6):660-72. doi: 10.1016/j.jmoldx.2014.06.004. Epub 2014 Aug 23.

PMID:
25157968
17.

Identifying suicidal symptoms in prostate cancer survivors using brief self-report.

Zhou ES, Hu JC, Kantoff PW, Recklitis CJ.

J Cancer Surviv. 2015 Mar;9(1):59-67. doi: 10.1007/s11764-014-0385-z. Epub 2014 Aug 19.

PMID:
25135206
18.

Role of androgen deprivation therapy in early salvage radiation among patients with prostate-specific antigen level of 0.5 or less.

Parekh A, Chen MH, Graham P, Mahal BA, Hirsch AE, Nakabayashi M, Evan C, Kantoff PW, Martin NE, Nguyen PL.

Clin Genitourin Cancer. 2015 Feb;13(1):e1-6. doi: 10.1016/j.clgc.2014.06.016. Epub 2014 Jun 27.

PMID:
25103271
19.

Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them.

Nguyen PL, Alibhai SM, Basaria S, D'Amico AV, Kantoff PW, Keating NL, Penson DF, Rosario DJ, Tombal B, Smith MR.

Eur Urol. 2015 May;67(5):825-836. doi: 10.1016/j.eururo.2014.07.010. Epub 2014 Aug 2. Review.

PMID:
25097095
20.

Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer.

McKay RR, Zukotynski KA, Werner L, Voznesensky O, Wu JS, Smith SE, Jiang Z, Melnick K, Yuan X, Kantoff PW, Montgomery B, Balk SP, Taplin ME.

Prostate Cancer Prostatic Dis. 2014 Dec;17(4):325-31. doi: 10.1038/pcan.2014.28. Epub 2014 Aug 5.

PMID:
25091040
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk